CN102526676A - 治疗慢性心力衰竭的中药、制备方法及给药方式 - Google Patents
治疗慢性心力衰竭的中药、制备方法及给药方式 Download PDFInfo
- Publication number
- CN102526676A CN102526676A CN2012100276544A CN201210027654A CN102526676A CN 102526676 A CN102526676 A CN 102526676A CN 2012100276544 A CN2012100276544 A CN 2012100276544A CN 201210027654 A CN201210027654 A CN 201210027654A CN 102526676 A CN102526676 A CN 102526676A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- chinese medicine
- hours
- mastic
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 108
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 28
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 28
- 235000008434 ginseng Nutrition 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 89
- 239000000843 powder Substances 0.000 claims description 56
- 239000013521 mastic Substances 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- 239000006187 pill Substances 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 36
- 239000009636 Huang Qi Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- 241000208340 Araliaceae Species 0.000 claims description 27
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 27
- 241000628997 Flos Species 0.000 claims description 26
- 238000005325 percolation Methods 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 230000001476 alcoholic effect Effects 0.000 claims description 15
- 239000003826 tablet Substances 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000001704 evaporation Methods 0.000 claims description 13
- 230000008020 evaporation Effects 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000002826 coolant Substances 0.000 claims description 12
- 229940008099 dimethicone Drugs 0.000 claims description 12
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 12
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 12
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 12
- 235000013599 spices Nutrition 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 150000001298 alcohols Chemical class 0.000 claims description 10
- 229940057995 liquid paraffin Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 7
- 235000011837 pasties Nutrition 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 238000009413 insulation Methods 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 48
- 238000011282 treatment Methods 0.000 abstract description 44
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 64
- 210000004369 blood Anatomy 0.000 description 63
- 210000002216 heart Anatomy 0.000 description 35
- 230000007812 deficiency Effects 0.000 description 32
- 206010019280 Heart failures Diseases 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 19
- 210000000952 spleen Anatomy 0.000 description 18
- 206010030113 Oedema Diseases 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 230000036407 pain Effects 0.000 description 15
- 206010011224 Cough Diseases 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 208000004880 Polyuria Diseases 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 12
- 230000035619 diuresis Effects 0.000 description 12
- 230000004217 heart function Effects 0.000 description 11
- 238000010792 warming Methods 0.000 description 11
- 208000000059 Dyspnea Diseases 0.000 description 10
- 206010013975 Dyspnoeas Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 206010033557 Palpitations Diseases 0.000 description 7
- 239000002934 diuretic Substances 0.000 description 7
- 230000001882 diuretic effect Effects 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 6
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 6
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 206010016807 Fluid retention Diseases 0.000 description 5
- 206010040007 Sense of oppression Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- -1 Ang II Proteins 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010030302 Oliguria Diseases 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000003177 cardiotonic effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 208000013116 chronic cough Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 231100001252 long-term toxicity Toxicity 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940068811 digitalis preparation Drugs 0.000 description 1
- 229940085080 digoxin 0.125 mg Drugs 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001880 fosinopril sodium Drugs 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 229940083558 furosemide 20 mg Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000008929 jingui shenqi Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 230000001053 orthosympathetic effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 230000009943 skeletal muscle blood flow Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
组别 | Nrats/只 | N存活/只 | P死亡/% |
治疗组 | 16 | 15 | 6.25 |
模型组 | 8 | 3 | 62.5 |
假手术组 | 8 | 8 | 100 |
组别 | 数量 | Ang II(pg·mL-1) | IL-6(pg·mL-1) | BNP(pg·mL-1) |
治疗组 | 15 | 110.36±10.26 | 149.82±12.86 | 4920±1797 |
模型组 | 3 | 169.12±26.61 | 197.02±36.91 | 7998±1246 |
假手术组 | 8 | 27.40±22.62 | 125.07±17.26 | 5080±2086 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210027654 CN102526676B (zh) | 2012-02-09 | 2012-02-09 | 治疗慢性心力衰竭的中药、制备方法及给药方式 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210027654 CN102526676B (zh) | 2012-02-09 | 2012-02-09 | 治疗慢性心力衰竭的中药、制备方法及给药方式 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102526676A true CN102526676A (zh) | 2012-07-04 |
CN102526676B CN102526676B (zh) | 2013-09-25 |
Family
ID=46335493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210027654 Active CN102526676B (zh) | 2012-02-09 | 2012-02-09 | 治疗慢性心力衰竭的中药、制备方法及给药方式 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102526676B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110877A (zh) * | 2012-12-10 | 2013-05-22 | 宋爱民 | 治疗风湿性心脏病的中药制剂 |
CN104758572A (zh) * | 2015-04-29 | 2015-07-08 | 赵振荣 | 一种治疗痰饮阻肺型心功能不全的药物及其制备方法 |
CN105193869A (zh) * | 2015-10-29 | 2015-12-30 | 北京岐黄制药有限公司 | 骨碎补及其提取物用于预防或治疗心衰的用途 |
CN105535504A (zh) * | 2016-01-22 | 2016-05-04 | 贾旭升 | 一种治疗心肺气虚型心功能衰竭的药物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1305844A (zh) * | 2001-01-14 | 2001-08-01 | 刘红 | 用于治疗充血性心力衰竭的药物 |
CN101322801A (zh) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备治疗扩张型心肌病药物中的应用 |
CN101653549A (zh) * | 2008-08-22 | 2010-02-24 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备治疗充血性心力衰竭药物中的应用 |
-
2012
- 2012-02-09 CN CN 201210027654 patent/CN102526676B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1305844A (zh) * | 2001-01-14 | 2001-08-01 | 刘红 | 用于治疗充血性心力衰竭的药物 |
CN101322801A (zh) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备治疗扩张型心肌病药物中的应用 |
CN101653549A (zh) * | 2008-08-22 | 2010-02-24 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备治疗充血性心力衰竭药物中的应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110877A (zh) * | 2012-12-10 | 2013-05-22 | 宋爱民 | 治疗风湿性心脏病的中药制剂 |
CN103110877B (zh) * | 2012-12-10 | 2014-08-13 | 宋爱民 | 治疗风湿性心脏病的中药制剂 |
CN104758572A (zh) * | 2015-04-29 | 2015-07-08 | 赵振荣 | 一种治疗痰饮阻肺型心功能不全的药物及其制备方法 |
CN105193869A (zh) * | 2015-10-29 | 2015-12-30 | 北京岐黄制药有限公司 | 骨碎补及其提取物用于预防或治疗心衰的用途 |
CN105535504A (zh) * | 2016-01-22 | 2016-05-04 | 贾旭升 | 一种治疗心肺气虚型心功能衰竭的药物 |
Also Published As
Publication number | Publication date |
---|---|
CN102526676B (zh) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102772748B (zh) | 一种治疗肝郁气滞型病毒性心肌炎的中药制剂及其制备方法 | |
CN103520694B (zh) | 治疗慢性阻塞性肺病稳定期的中药组合物及其制备方法 | |
CN101524469B (zh) | 一种治疗充血性心力衰竭的中药复方制剂及其制备方法 | |
CN103202879B (zh) | 一种治疗慢性心力衰竭的中药组合物及制备方法 | |
CN102526676B (zh) | 治疗慢性心力衰竭的中药、制备方法及给药方式 | |
CN111643591A (zh) | 一种健脾益肾中药组合物及其应用 | |
CN111729064A (zh) | 一种健脾通阳中药组合物及其应用 | |
CN104147345B (zh) | 一种治疗心脏自主神经病变的中药组合物 | |
CN102120020A (zh) | 一种治疗乳腺增生病和子宫肌瘤的药物组合物及其制备方法 | |
CN101537159B (zh) | 一种中药组合物及其制备方法和应用 | |
CN103182012A (zh) | 一种治疗缺血性脑中风的药物及其制备方法 | |
CN103977362A (zh) | 治疗乳腺增生及早期乳腺癌的中药组方 | |
CN101670090A (zh) | 一种治疗中晚期恶性肿瘤的药物组合物及其制备方法 | |
CN104083728B (zh) | 抗癌消瘤浓缩丸的加工方法 | |
CN103655786B (zh) | 一种治疗高尿酸血症和痛风的中药组合物 | |
CN104707090A (zh) | 一种治疗冠心病的中药组方 | |
CN101214314A (zh) | 治疗脑中风的中药 | |
CN105055967B (zh) | 一种具有辅助降血糖功能的复方保健品及制备方法 | |
CN103191399A (zh) | 用于治疗支气管哮喘急性发作期的中药组合物 | |
CN106421559A (zh) | 一种治疗高尿酸血症的中药制剂及其制备方法 | |
CN102293985A (zh) | 用于治疗冠心病的中药组合物及其制备方法 | |
CN102274357B (zh) | 一种治疗冠状动脉硬化性心脏病的药物组合物及其制备方法 | |
CN104398789A (zh) | 一种治疗缺铁性贫血的中药汤剂 | |
CN101249145B (zh) | 一种安神中药组合物及其制备更年期综合症药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: QINGDAO HUAREN TECHNOLOGY INCUBATOR CO., LTD. Free format text: FORMER OWNER: LIU SIJUAN Effective date: 20130830 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 237221 LU'AN, ANHUI PROVINCE TO: 266071 QINGDAO, SHANDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130830 Address after: 266071 Shandong city of Qingdao province Hongkong City Road No. 32 floor 801-A room 8 Applicant after: Qingdao Huaren Technology Incubator Co., Ltd. Address before: 237221, No. 35, Xia Jie Qiao street, Mount Holyoke County, Anhui Applicant before: Liu Sijuan |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: QINGDAO HUAREN TECHNOLOGY INCUBATOR CO., LTD. Effective date: 20141231 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266071 QINGDAO, SHANDONG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141231 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 266071 Shandong city of Qingdao province Hongkong City Road No. 32 floor 801-A room 8 Patentee before: Qingdao Huaren Technology Incubator Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200410 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210820 Address after: 226400 No.8, wisdom Avenue, Donghu scenic area, Dayu Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Nantong Donghu International Travel Agency Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
TR01 | Transfer of patent right |